Karenza Alexis

Daiichi Sankyo (United States) — United States

Medicine · Health Sciences

11h-index464citations30works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(8), Lymphoma Diagnosis and Treatment(6), Cancer Treatment and Pharmacology(6), Economic and Financial Impacts of Cancer(5), Immune Cell Function and Interaction(4)

Publications30 total

QUANTUM-WILD: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB IN COMBINATION WITH CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN FLT3-ITD–NEGATIVE ACUTE MYELOID LEUKEMIA
Hematology Transfusion and Cell Therapy·2025Open Access
Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results
Blood·2023· 19 cited
AFM13 in Combination with Allogeneic Natural Killer Cells (AB-101) in Relapsed or Refractory Hodgkin Lymphoma and CD30 + Peripheral T-Cell Lymphoma: A Phase 2 Study (LuminICE)
Blood·2023· 11 cited
P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY
HemaSphere·2023· 4 citedOpen Access
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (<i>R</i>/<i>R</i>) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY
Hematological Oncology·2023Open Access
Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)
Cancer Research·2023· 14 cited
Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma
Blood·2022· 23 cited
Abstract CT003: Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma
Cancer Research·2022· 16 cited
Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
Scientific Reports·2020· 12 citedOpen Access
A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.
Journal of Clinical Oncology·2020· 9 cited
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Breast Cancer·2020· 72 citedOpen Access
Abstract P4-10-08: Absolute lymphocyte count (ALC) is a predictor of eribulin benefit in advanced or metastatic breast cancer (MBC)
Cancer Research·2020
Observational Study of Clinical Outcomes of Eribulin Mesylate in Metastatic Breast Cancer After Cyclin-Dependent Kinase 4/6 Inhibitor Therapy
Future Oncology·2019· 17 citedOpen Access
Real-world 1-year survival analysis of patients with metastatic breast cancer with liver or lung metastasis treated with eribulin, gemcitabine or capecitabine
Annals of Oncology·2019· 2 citedOpen Access
Utilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER)
Annals of Oncology·2019· 1 cited
What Is the Patient Risk from a Bone Marrow Biopsy By Hematologists-in-Training? A Prospective, Clinical Study
Blood·2017
Targeting the anterior superior iliac spine yields significantly longer bone marrow cores
Journal of Clinical Pathology·2017· 4 cited
Economic, Transfusion, and Efficacy Outcomes with the Addition of IV Iron Sucrose to Oral Iron Therapy in Pregnancy Associated Iron Deficiency Anemia
Blood·2016
Doing better with less: Can a quality improvement intervention to increase adherence to evidence-based cancer screening guidelines reduce health care costs?
Journal of Clinical Oncology·2016
(213) Do mental health disorders impact patients' report of pain in head and neck cancer?
Journal of Pain·2016Open Access
page 1 of 2Next →

Frequent Co-authors

Marianna Strakhan(11), Tarek N. Elrafei(11), Michael Emig(6), Richard J. Gralla(6), Louis Juden Reed(6), A. Harstrick(4), Ahmed Sawas(4), Andre Overesch(4), Javier Cortés(3), Yago Nieto(3), Pinaki P. Banerjee(3), Indreshpal Kaur(3), Lori A. Griffin(3), Christina Ganesh(3), Lucila Nassif Kerbauy(3), Rafet Başar(3), Mecit Kaplan(3), Daniel Esqueda(3), Jeremy Ramdial(3), Samer A. Srour(3)